FDG: manuscripts

• **published** manuscripts acknowledging QIBA profile:
• **in progress** manuscripts: Kinahan et al. manuscript describing profile. To be submitted by 30 June 2019
other deliverables

• 2Q2019: test-retest multicenter still a GO!
• 3Q2019: collaborative white paper for PET-MR quantification
• adding use cases to profile
• embed QIBA profile into NCTN multi-center trials

timeline for amyloid profile

• 4Q2019: technical confirmation to be completed by:
  • 3Q2019: addressing 2-4 remaining technical questions
  • 4Q2019: completing the conformance section (DRO)
  • 4Q2019: confirming actual implementation by 2 sites
• deployment before 1Q2020
high level time line for ioflupane profile

- 2Q2019 finish version 2.0 of profile
- 3Q2019 broadcast request for public comment —
- 3Q2019 pxp response to public comment
- 3Q2019 conformance testing at 3 sites
- **4Q2019 deployment**

ioflupane: new business

- QIBA-Japan: unique ioflupane groundwork
- add use cases: Kinahan has started the process
time-line for $[^{99mTc}]$ deliverables

- 2Q2019 finalize current version
- 3Q2019 public comments
- 3Q2019
  - respond to comments
  - begin conformance testing
- add use cases
- **4Q2019 deployment**

future business

- funding external (updates by Dr. Jackson)
  - initial target = pharma; all CCs submitted lists
- funding internal (predominantly NIH)
  - FDG brain ground work on repeatability
  - additional PET/MR repeatability
  - dynamic whole body acquisitions
  - FDG test-retest ground work (shovel ready)
- [68Ga]-PSMA, [68Ga]-DOTA TATE, [177Lu]-PSMA, [Y90]microspheres
- gazillion SPECT projects